One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...

Isomorphic Labs is a London-based drug developer that’s owned and operated by Alphabet Inc. The company was founded in 2021 ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Isomorphic Labs, backed by Google's parent company Alphabet, is preparing for its first human clinical trials for cancer drugs designed entirely by artificial intelligence.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is “staffing up” ...

Alphabet has now taken that advancement and created a new company called Isomorphic Labs, focused on AI-driven drug discovery. This commercial venture was founded and is currently led by DeepMind ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led ...

Isomorphic Labs Inc., a healthcare startup that spun out of Alphabet Inc. in 2021, today announced that it has closed a $600 million funding round.OpenAI backer Thrive Capital led the investment.

Isomorphic Labs, a subsidiary of Alphabet Inc., said it entered into strategic research collaboration agreements with Novartis AG and Eli Lilly & Co.